Novavax (NVAX) Interest Coverage Ratio Growth (1y) (2011 - 2026)
Novavax (NVAX) Interest Coverage Ratio Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -347.04% |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 1,378.45% |
| 10 | Novavax | 1.26 Bn | 467.27 Mn | 108.82 Mn | -102.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.72% |
| Dec 31, 2025 | 157.40% |
| Sep 30, 2025 | 26.45% |
| Jun 30, 2025 | -52.87% |
| Mar 31, 2025 | 355.68% |
| Dec 31, 2024 | 92.84% |
| Sep 30, 2024 | 28.00% |
| Jun 30, 2024 | 118.91% |
| Mar 31, 2024 | 26.04% |
| Dec 31, 2023 | -2,279.03% |
| Sep 30, 2023 | -44.04% |
| Jun 30, 2023 | 122.91% |
| Mar 31, 2023 | -251.44% |
| Dec 31, 2022 | 68.22% |
| Sep 30, 2022 | 48.53% |
| Jun 30, 2022 | -33.69% |
| Mar 31, 2022 | 213.52% |
| Dec 31, 2021 | 92.90% |
| Sep 30, 2021 | -13,545.65% |
| Jun 30, 2021 | -1,058.13% |